Recent News

• 03.28.2025 - Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 03.28.2025 - Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 03.25.2025 - Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
• 03.25.2025 - Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
• 03.25.2025 - Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
• 03.25.2025 - Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
• 03.25.2025 - Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
• 03.25.2025 - Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock
• 03.25.2025 - Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer
• 03.25.2025 - Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease

Recent Filings

• 03.28.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.28.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.25.2025 - EX-99.1 EX-99.1
• 03.25.2025 - 8-K Current report
• 03.25.2025 - 8-K Current report
• 03.25.2025 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 03.25.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.25.2025 - EX-99.1 EX-99.1